Grace Therapeutics Receives FDA Meeting Minutes and Advances NDA Resubmission Strategy for GTx-104
Key Points for Investors
- FDA Type A Meeting Minutes Received: Grace Therapeutics has received the official minutes from a recent Type A Meeting with the U.S. Food and Drug Administration (FDA).
- No Clinical Safety or Efficacy Deficiencies Identified: The FDA did not find any clinical safety or efficacy issues with GTx-104, nor did it request additional clinical data.
- Manufacturing & Compliance Are Central Issues: The FDA’s Complete Response Letter (CRL) only cited facility-level current good manufacturing practice (cGMP) compliance issues at the Company’s contract manufacturing organization (CMO), not product-specific quality deficiencies.
- Dual-Source Manufacturing Strategy Initiated: The company is adding a U.S.-based contract manufacturer to reduce reliance on a single supplier and to address the FDA’s concerns, potentially accelerating the NDA resubmission and approval process.
- GTx-104 Clinical Data Remain Strong: In the pivotal STRIVE-ON trial, GTx-104 met its primary endpoint over oral nimodipine, showing reduced drug-induced hypotension and other clinical benefits.
- Orphan Drug Designation & Extensive IP: GTx-104 holds FDA Orphan Drug Designation and is protected by 52 granted and pending patents, offering potential seven-year marketing exclusivity post-approval.
Detailed Developments
Regulatory Pathway and Progress
Grace Therapeutics (Nasdaq: GRCE) announced a significant regulatory milestone with the receipt of official FDA meeting minutes following a Type A Meeting. This meeting was convened to address the Complete Response Letter (CRL) issued on April 23, 2026, for GTx-104, the company’s lead asset for aneurysmal Subarachnoid Hemorrhage (aSAH).
Critically, the FDA did not cite any clinical safety or efficacy deficiencies for GTx-104 and did not request new clinical trials—a major de-risking event for shareholders. The only remaining hurdles are related to the manufacturing process, specifically cGMP compliance at the company’s current contract manufacturing facility. Additional requirements include providing further leachables data and excipient toxicology risk assessments, which the company intends to address in its upcoming NDA resubmission.
In response, Grace Therapeutics is pursuing a dual-source manufacturing strategy. Its current manufacturer is remediating the cGMP issues and preparing for a possible FDA reinspection, while, in parallel, the company is transferring manufacturing technology to a second, U.S.-based CMO. This diversification reduces reliance on a single manufacturing site and increases the probability of a timely and successful resubmission and approval. The NDA resubmission can be supported by either or both manufacturers, depending on which is inspection-ready first.
Clinical Results: STRIVE-ON Trial
The pivotal STRIVE-ON trial (NCT05995405) compared GTx-104 (IV nimodipine) with standard oral nimodipine in aSAH patients. Among 102 patients (50 GTx-104; 52 oral nimodipine), GTx-104 demonstrated:
- 19% reduction in clinically significant hypotension episodes (28% for GTx-104 vs. 35% for oral nimodipine).
- 54% of GTx-104 patients had dose intensity ≥95% vs. only 8% for oral nimodipine.
- 29% more GTx-104 patients achieved favorable functional outcomes at 90 days.
- Fewer ICU readmissions, ICU days, and ventilator days for GTx-104 patients.
- Adverse events were similar between arms. All deaths (8 on GTx-104, 4 on oral nimodipine, 1 unknown in oral group) were attributed to the underlying severity of aSAH, not the study drugs.
Product Profile and Market Potential
GTx-104 is a novel, injectable nanoparticle nimodipine for IV use, potentially transforming aSAH management by eliminating the need for nasogastric tube administration in unconscious or dysphagic patients, reducing drug-to-drug interactions, minimizing dosing errors, and better managing hypotension.
With over 200 patients and healthy volunteers exposed in clinical studies, GTx-104 has demonstrated excellent tolerability and lower pharmacokinetic variability compared to oral nimodipine. The product’s Orphan Drug Designation and strong intellectual property portfolio (52 patents) further enhance its commercial prospects and create significant barriers to competition.
Implications for Shareholders
- Major Regulatory De-Risking: The absence of clinical deficiencies means the regulatory path forward is centered on manufacturing—a resolvable issue, rather than needing new trials, which is positive and potentially price-sensitive.
- Diversified Manufacturing Reduces Risk: The dual-source strategy enhances the likelihood of timely NDA approval, reducing regulatory and operational risk.
- Strong Clinical and Market Positioning: GTx-104’s clinical benefits and orphan status suggest a compelling potential for market adoption, reimbursement, and pricing power upon approval.
- Investors Should Monitor: Progress on cGMP remediation, FDA reinspection outcomes, and technology transfer milestones to the U.S.-based CMO, as well as forthcoming NDA resubmission timing—all of which are share price catalysts.
Forward-Looking Statements
Management emphasizes that forward-looking statements involve risks, including regulatory resubmission timing, FDA reinspection outcomes, successful technology transfer, completion of non-clinical studies, additional capital needs, and broader market and regulatory conditions. Investors are urged not to place undue reliance on these statements and to review the Company’s filings for a full risk assessment.
Contact
For further information, investors may contact:
Prashant Kohli, Chief Executive Officer, [email protected], 609-322-1602
Investor Relations: Mike Moyer, LifeSci Advisors, [email protected], 617-308-4306
www.gracetx.com
Disclaimer: This article is for informational purposes only and does not constitute investment advice. All forward-looking statements are based on current expectations and involve risks and uncertainties. Investors should conduct their own due diligence or consult a financial advisor before making investment decisions. The author assumes no responsibility for investment decisions based on this content.
